Dark

LUNG
Pulmonx Corporation Common Stock
stock NASDAQ

At Close

Aug 29, 2025 3:59:30 PM EDT

1.71USD-3.125%(-0.06)398,430

0.00Bid 0.00Ask 0.00Spread

Pre-market

Aug 28, 2025 9:28:30 AM EDT

1.88USD+6.818%(+0.12)0

After-hours

Aug 28, 2025 4:11:30 PM EDT

1.76USD+0.571%(+0.01)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 7, 2022

01:07PM EST Morgan Stanley Maintains Equal-Weight on Pulmonx, Lowers Price Target to $37 Benzinga

Dec 29, 2021

04:05PM EST Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx) a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming 40th Annual J.P. Morgan Healthcare Conference. Management is scheduled to present on Tuesday, January 11, 2022, at 7:30 a.m. Eastern Standard Time. GlobeNewswire Inc

Dec 8, 2021

10:04AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021 Benzinga

05:10AM EST Piper Sandler Upgrades Pulmonx to Overweight, Announces $45 Price Target Benzinga

Nov 16, 2021

04:05PM EST Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx) a global leader in minimally invasive treatments for severe lung disease, today announced the company will participate in the 33rd Annual Piper Sandler Healthcare Conference being held from November 29 to December 2, 2021. Members of the management team will be participating in investor meetings on Wednesday, December 1, 2021. GlobeNewswire Inc

Nov 3, 2021

09:20AM EDT Wells Fargo Maintains Equal-Weight on Pulmonx, Lowers Price Target to $55 Benzinga

08:00AM EDT Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming virtual investor conferences. GlobeNewswire Inc

Nov 2, 2021

05:11PM EDT Pulmonx Reiterates FY21 Guidance Benzinga

05:11PM EDT Pulmonx Q3 EPS $(0.28) Beats $(0.37) Estimate, Sales $13.30M Beat $13.18M Estimate Benzinga

10:54AM EDT The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US Benzinga

10:41AM EDT Earnings Scheduled For November 2, 2021 Benzinga

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 26, 2021

04:05PM EDT Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2021 after the close of trading on Tuesday, November 2, 2021. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT/4:30 p.m. ET. GlobeNewswire Inc

Sep 21, 2021

04:12PM EDT Pulmonx Reports 2 Added Blue Cross Blue Shield Plans Now Provide Coverage For Severe Emphysema/COPD Treatment Benzinga

Aug 26, 2021

04:05PM EDT Pulmonx to Present at Upcoming September Investor Conferences GlobeNewswire Inc

Aug 20, 2021

04:39PM EDT Pulmonx Announces Anthem Blue Cross Blue Shield Now Provides Coverage For Severe COPD/Emphysema Treatment Benzinga

01:52PM EDT Return on Capital Employed Overview: Pulmonx Benzinga

Aug 4, 2021

12:14PM EDT Canaccord Genuity Maintains Buy on Pulmonx, Lowers Price Target to $53 Benzinga

Aug 3, 2021

04:48PM EDT Pulmonx Sees FY21 Sales $49M-$51M vs $49.2M Est. Benzinga

04:47PM EDT Pulmonx Q2 EPS $(0.34) Up From $(0.37) YoY, Sales $12.20M Beat $10.51M Estimate Benzinga

07:55AM EDT The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business Benzinga

03:52AM EDT Earnings Scheduled For August 3, 2021 Benzinga

Aug 2, 2021

08:45AM EDT Pulmonx Welcomes Two New Board Members, Adding Expertise in Health GlobeNewswire Inc

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 27, 2021

11:13AM EDT Pulmonx Announces Long-Term Follow-Up Data On Zephyr Valve Benzinga

Jul 20, 2021

04:05PM EDT Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2021 after the close of trading on Tuesday, August 3, 2021. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT/4:30 p.m. ET. GlobeNewswire Inc

May 17, 2021

04:26PM EDT Pulmonx Corporation Highlights Presentation Of Long-Term Follow-Up Data From TRANSFORM Study At American Thoracic Society Virtual 2021 International Conference. Benzinga

04:05PM EDT Zephyr Valve Treatment Provides Long-Term Quality of GlobeNewswire Inc

May 14, 2021

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

May 4, 2021

04:36PM EDT Pulmonx Q1 EPS $(0.34) Beats $(0.38) Estimate, Sales $9.20M Beat $8.14M Estimate Benzinga

04:02PM EDT Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today reported financial results for the first quarter ended March 31, 2021. GlobeNewswire Inc

04:01PM EDT Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx) a global leader in minimally invasive treatments for severe lung disease, today announced the appointment of Michael Ryan as Vice President, Corporate Strategy and Business Development, and the earlier appointments of David Lehman as General Counsel, and Mahtab Fatemi as Vice President, Regulatory Affairs and Quality Assurance. GlobeNewswire Inc

Apr 27, 2021

04:05PM EDT Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx) a global leader in minimally invasive treatments for lung disease, today announced the company will be participating in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021 at 8:00am PT / 11:00am ET. GlobeNewswire Inc

Apr 20, 2021

04:05PM EDT Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2021 after the close of trading on Tuesday, May 4, 2021. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT/4:30 p.m. ET. GlobeNewswire Inc

Apr 1, 2021

10:49AM EDT Citigroup Initiates Coverage On Pulmonx with Buy Rating, Announces Price Target of $60 Benzinga

Mar 25, 2021

10:17AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 25, 2021 Benzinga

06:18AM EDT Piper Sandler Initiates Coverage On Pulmonx with Neutral Rating, Announces Price Target of $50 Benzinga

Mar 10, 2021

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2021 Benzinga

08:55AM EST B of A Securities Upgrades Pulmonx to Buy, Announces $72 Price Target Benzinga

Mar 3, 2021

09:08AM EST Canaccord Genuity Maintains Buy on Pulmonx, Raises Price Target to $65 Benzinga

08:30AM EST Morgan Stanley Maintains Equal-Weight on Pulmonx, Raises Price Target to $53 Benzinga

Mar 2, 2021

04:03PM EST Pulmonx Corp Sees Q1 Sales $8.0M-$8.3M Vs. $8.82M Est., FY21 Sales $46M-$50M Vs. $46.53M Est. Benzinga

04:02PM EST Pulmonx Q4 EPS $(0.27) Beats $(0.28) Estimate, Sales $9.83M Beat $8.81M Estimate Benzinga

04:01PM EST Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2020 ended December 31, 2020. GlobeNewswire Inc

03:40AM EST Earnings Scheduled For March 2, 2021 Benzinga

Feb 16, 2021

04:01PM EST Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2020 after the close of trading on Tuesday, March 2, 2021. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT/4:30 p.m. ET. GlobeNewswire Inc

Jan 28, 2021

09:04AM EST JTV(r), Pulmonx(r) Corporation & Respiratory Health Association(r) Launch 2021 PR Newswire

Dec 23, 2020

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 15, 2020

12:54PM EST Morgan Stanley Maintains Equal-Weight on Pulmonx, Raises Price Target to $52 Benzinga

Dec 8, 2020

08:13AM EST Pulmonx Welcomes Two New Members to Its Board of Directors, Adding GlobeNewswire Inc

Dec 1, 2020

08:08AM EST The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit Benzinga

Nov 30, 2020

08:00AM EST The Zephyr Valve Helps COPD/Emphysema Patients Breathe Easier Without the Risk of Major Surgery1 GlobeNewswire Inc

Nov 25, 2020

07:35AM EST The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback Benzinga

Nov 11, 2020

08:15AM EST Morgan Stanley Maintains Equal-Weight on Pulmonx, Raises Price Target to $46 Benzinga

Nov 10, 2020

04:07PM EST Pulmonx Sees FY20 Revs. $31.5M To $32M Benzinga

04:06PM EST Pulmonx Q3 EPS $(1.37) Beats $(4.32) Estimate, Sales $10.60M Beat $8.37M Estimate Benzinga

04:01PM EST Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a commercial-stage medical technology company that provides minimally invasive treatment for patients with severe emphysema, a form of COPD, today reported financial results for the third quarter ended September 30, 2020. GlobeNewswire Inc

Nov 3, 2020

08:00AM EST Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx) today announced the company will be participating in two upcoming virtual investor conferences. GlobeNewswire Inc

Nov 2, 2020

10:01AM EST Pulmonx Announces Additional 16M 'Covered Lives' For The Zephyr Valve Benzinga

10:00AM EST Pulmonx Announces Additional 16 Million Covered Lives for The GlobeNewswire Inc

Oct 26, 2020

12:32PM EDT B of A Securities Initiates Coverage On Pulmonx with Buy Rating, Announces Price Target of $50 Benzinga

10:08AM EDT Canaccord Genuity Initiates Coverage On Pulmonx with Buy Rating, Announces Price Target of $49 Benzinga

10:08AM EDT Benzinga's Top Upgrades, Downgrades For October 26, 2020 Benzinga

06:22AM EDT Stifel Initiates Coverage On Pulmonx with Buy Rating, Announces Price Target of $50 Benzinga

06:20AM EDT Morgan Stanley Initiates Coverage On Pulmonx with Equal-Weight Rating, Announces Price Target of $44 Benzinga

06:19AM EDT Wells Fargo Initiates Coverage On Pulmonx with Equal-Weight Rating, Announces Price Target of $46 Benzinga

Oct 22, 2020

04:01PM EDT Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2020 after the close of trading on Tuesday, November 10, 2020. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT/4:30 p.m. ET. GlobeNewswire Inc

Oct 11, 2020

11:35AM EDT Last Week's Notable Insider Buys: Element Solutions, Selecta Biosciences And More Benzinga

Oct 5, 2020

04:19PM EDT Pulmonx Corp Director Mead Jr Buys 26,315 Shares @$19/Share Benzinga

04:01PM EDT Pulmonx Announces Closing of Initial Public Offering and Full GlobeNewswire Inc

Oct 1, 2020

11:32AM EDT Pulmonx Corporation Shares Open For Trade At $40; IPO Priced At $19/Share Benzinga

10:57AM EDT Pulmonx Shares Indicating $35 On 450K Shares Benzinga

09:56AM EDT Pulmonx Corporation Expected To Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT; IPO Priced At $19.00/Share Benzinga

05:45AM EDT Pulmonx Corporation Priced Upsized 10M Share IPO @$19/Share Benzinga

Sep 30, 2020

10:36PM EDT Pulmonx Corporation Announces Pricing of its Upsized Initial GlobeNewswire Inc